Hitomi Sakai
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).
Journal: Breast cancer research and treatment
Published: March 30, 2026
Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.
Journal: International journal of clinical oncology
Published: March 20, 2026
Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.
Journal: International journal of clinical oncology
Published: March 20, 2026
BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).
Journal: Breast cancer (Tokyo, Japan)
Published: February 24, 2026
Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study.
Journal: Future oncology (London, England)
Published: October 24, 2025
Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).
Journal: Breast cancer (Tokyo, Japan)
Published: September 22, 2025
Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: June 23, 2025
Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).
Journal: Breast cancer (Tokyo, Japan)
Published: December 04, 2024
Management of nausea and vomiting induced by antibody-drug conjugates.
Journal: Breast cancer (Tokyo, Japan)
Published: November 11, 2024
Awareness and attitude toward cardio-oncology among Japanese gynecologic oncologists in managing patients with endometrial cancer: The Japanese Gynecologic Oncology Group (JGOG) questionnaire surveys.
Journal: The journal of obstetrics and gynaecology research
Published: October 03, 2024
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 29, 2024
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Journal: Current medical research and opinion
Published: April 10, 2024
Last Updated: 09/26/2026